Brain lesions in patients with AIDS: H-1 MR spectroscopy.

Chang, Linda; Miller, B L; McBride, Duncan Q.; Cornford, Marcia E.; Oropilla, Grace; Buchthal, Steven; Chiang, Frances; Aronow, Howard; Beck, Cathy; Ernst, Thomas

doi:10.1148/radiology.197.2.7480706

Cited by 135 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 1.3 ppm peak is several times taller than the 0.9 ppm peak in the mobile lipids commonly seen in toxoplasmosis, lymphomas and high-grade gliomas. Approximately equal-sized peaks have been seen in Zellweger syndrome (11,12), an example of which will be shown below and progressive multifocal leukoencephalopathy (PML) (13)(14)(15)(16)(17)(18). In contrast, a single broad peak usually indicates contamination with skull lipids.…”

Section: Appearance Of Lipid Peaksmentioning

confidence: 99%

Identification of diffuse and focal brain lesions by clinical magnetic resonance spectroscopy

2006

View full text Add to dashboard Cite

The purpose of this paper is to facilitate the comparison of magnetic resonance (MR) spectra acquired from unknown brain lesions with published spectra in order to help identify unknown lesions in clinical settings. The paper includes lists of references for published MR spectra of various brain diseases, including pyogenic abscesses, encephalitis (herpes simplex, Rasmussen's and subacute sclerosing panencephalitis), neurocysticercosis, tuberculoma, cysts (arachnoid, epidermoid and hydatid), acute disseminated encephalomyelitis (ADEM), adrenoleukodystrophy (ALD), Alexander disease, Canavan's disease, Krabbe disease (globoid cell leukodystrophy), Leigh's disease, megalencephalic leukoencephalopathy with cysts, metachromatic leukodystrophy (MLD), Pelizaeus-Merzbacher disease, Zellweger syndrome, HIV-associated lesions [cryptococcus, lymphoma, toxoplasmosis and progressive multifocal leukoencephalopathy (PML)], hydrocephalus and tuberous sclerosis. Each list includes information on the echo time(s) (TE) of the published spectra, whether a control spectrum is shown, whether the corresponding image and voxel position are shown and the patient ages if known. The references are listed in the approximate order of usefulness, based on spectral quality, number of spectra, range of echo times and whether the voxel positions are shown. Spectra of Zellweger syndrome, cryptococcal infection, toxoplasmosis and lymphoma are included, along with a spectrum showing propanediol (propylene glycol).

show abstract

Section: Appearance Of Lipid Peaksmentioning

confidence: 99%

Identification of diffuse and focal brain lesions by clinical magnetic resonance spectroscopy

2006

View full text Add to dashboard Cite

show abstract

“…Fortunately, MRS can easily differentiate between each of the conditions as each provides a unique metabolic signature. 26 Toxoplasmosis has decreased mI, Cho, Cr, and NAA with a 15-to 20-fold increase in lactate/lipids. CNS lymphomas have increased Cho, lactate, and lipids (but on the same order of magnitude) as well as decreased NAA and mI.…”

Section: Human Immunodeficiency Virus Dementia and Lesionsmentioning

confidence: 99%

Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making

Lin¹,

Ross²,

Harris³

et al. 2005

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Anatomic and functional neuroimaging with magnetic resonance imaging (MRI) includes the technology more widely known as magnetic resonance spectroscopy (MRS). Now a routine automated "add-on" to all clinical magnetic resonance scanners, MRS, which assays regional neurochemical health and disease, is therefore the most accessible diagnostic tool for clinical management of neurometabolic disorders. Furthermore, the noninvasive nature of this technique makes it an ideal tool for therapeutic monitoring of disease and neurotherapeutic decision making. Among the more than 100 brain disorders that fall within this broad category, MRS contributes decisively to clinical decision making in a smaller but growing number. In this review, we will cover how MRS provides therapeutic impact in brain tumors, metabolic disorders such as adrenoleukodystrophy and Canavan's disease, Alzheimer's disease, hypoxia, secondary to trauma or ischemia, human immunodeficiency virus dementia and lesions, as well as systemic disease such as hepatic and renal failure. Together, these eight indications for MRS apply to a majority of all cases seen. This review, which examines the role of MRS in enhancing routine neurological practice and treatment concludes: 1) there is added value from MRS where MRI is positive; 2) there is unique decision-making information in MRS when MRI is negative; and 3) MRS usefully informs decision making in neurotherapeutics. Additional efficacy studies could extend the range of this capability.

show abstract

“…In contrast, 1 H MRS can detect much smaller tumors (1-2 cm 3 at 1.5 T) with the same signal-to-noise ratio as 31 P MRS at the same acquisition time (25). Proton MRS has been demonstrated to be useful in differentiating between cancer, necrosis, and normal tissue of various organs such as brain (26)(27)(28), prostate (29), neck (28), breast (30,31), kidney (32) and liver (33).…”

Section: Introductionmentioning

confidence: 99%

In Vivo Monitoring Response to Chemotherapy of Human Diffuse Large B-Cell Lymphoma Xenografts in SCID Mice by 1H and 31P MRS

Huang¹,

Nelson²,

Pickup³

et al. 2007

Academic Radiology

View full text Add to dashboard Cite

Rationale and Objectives-A reliable non-invasive method for in vivo detection of early therapeutic response of non-Hodgkin's lymphoma (NHL) patients would be of great clinical value. This study evaluates the feasibility of 1 H and 31 P magnetic resonance spectroscopy (MRS) for in vivo detection of response to combination chemotherapy of human diffuse large B-cell lymphoma (DLCL2) xenografts in SCID mice.Materials and Methods. C-ombination chemotherapy with Cyclophosphamide, Hydroxydoxorubicin, Oncovin, Prednisone, and Bryostatin 1 (CHOPB) was administered to tumorbearing SCID mice weekly for up to four cycles. Spectroscopic studies were performed before the initiation of treatment and after each cycle of the CHOPB. Proton MRS for detection of lactate and total choline was performed using a selective multiple-quantum-coherence-transfer (Sel-MQC) and a spin-echo-enhanced Sel-MQC (SEE-Sel-MQC) pulse sequence, respectively. Phosphorus-31 MRS utilizing a non-localized single-pulse sequence without proton decoupling was performed on these animals.Results-Significant decreases in lactate and total choline were detected in the DLCL2 tumors after one cycle of CHOPB chemotherapy. The ratio of phosphomonoesters to β-nucleoside triphosphate (PME/βNTP, measured by 31 P MRS) significantly decreased in the CHOPB treated tumors after two cycles of CHOPB. The control tumors did not exhibit any significant changes in either of these metabolites.Conclusions-This study demonstrates that 1 H MRS and 31 P MRS can detect in vivo therapeutic response of NHL tumors and that lactate and choline offer a number of advantages over PMEs as markers of early therapeutic response.

show abstract

Brain lesions in patients with AIDS: H-1 MR spectroscopy.

Abstract: H-1 MR spectroscopy is a sensitive and potentially specific noninvasive adjunctive method for differential diagnosis of focal brain lesions in AIDS.

Cited by 135 publications

References 0 publications

Identification of diffuse and focal brain lesions by clinical magnetic resonance spectroscopy

Identification of diffuse and focal brain lesions by clinical magnetic resonance spectroscopy

Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making

In Vivo Monitoring Response to Chemotherapy of Human Diffuse Large B-Cell Lymphoma Xenografts in SCID Mice by 1H and 31P MRS

Contact Info

Product

Resources

About